| |  Online-Ressource |
|---|
| Verfasst von: | Schetelig, Johannes [VerfasserIn]  |
|---|
| | Schaich, M. [VerfasserIn] |
|---|
| | Schäfer-Eckart, K. [VerfasserIn] |
|---|
| | Hänel, M. [VerfasserIn] |
|---|
| | Aulitzky, W. E. [VerfasserIn] |
|---|
| | Einsele, H. [VerfasserIn] |
|---|
| | Schmitz, N. [VerfasserIn] |
|---|
| | Rösler, W. [VerfasserIn] |
|---|
| | Stelljes, M. [VerfasserIn] |
|---|
| | Baldus, C. D. [VerfasserIn] |
|---|
| | Ho, Anthony Dick [VerfasserIn] |
|---|
| | Neubauer, A. [VerfasserIn] |
|---|
| | Serve, H. [VerfasserIn] |
|---|
| | Mayer, J. [VerfasserIn] |
|---|
| | Berdel, W. E. [VerfasserIn] |
|---|
| | Mohr, B. [VerfasserIn] |
|---|
| | Oelschlägel, U. [VerfasserIn] |
|---|
| | Parmentier, S. [VerfasserIn] |
|---|
| | Röllig, C. [VerfasserIn] |
|---|
| | Kramer, M. [VerfasserIn] |
|---|
| | Platzbecker, U. [VerfasserIn] |
|---|
| | Illmer, T. [VerfasserIn] |
|---|
| | Thiede, C. [VerfasserIn] |
|---|
| | Bornhäuser, M. [VerfasserIn] |
|---|
| | Ehninger, G. [VerfasserIn] |
|---|
| Titel: | Hematopoietic cell transplantation in patients with intermediate and high-risk AML |
|---|
| Titelzusatz: | results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial |
|---|
| Verf.angabe: | J Schetelig, M Schaich, K Schäfer-Eckart, M Hänel, WE Aulitzky, H Einsele, N Schmitz, W Rösler, M Stelljes, CD Baldus, AD Ho, A Neubauer, H Serve, J Mayer, WE Berdel, B Mohr, U Oelschlägel, S Parmentier, C Röllig, M Kramer, U Platzbecker,T Illmer, C Thiede, M Bornhäuser and G Ehninger on behalf of the Study Alliance Leukemia (SAL) |
|---|
| Jahr: | 2015 |
|---|
| Jahr des Originals: | 2014 |
|---|
| Umfang: | 9 S. |
|---|
| Fussnoten: | Published: 01 December 2014 ; Gesehen am 18.06.2020 |
|---|
| Titel Quelle: | Enthalten in: Leukemia |
|---|
| Ort Quelle: | London : Springer Nature, 1997 |
|---|
| Jahr Quelle: | 2015 |
|---|
| Band/Heft Quelle: | 29(2015), 5, Seite 1060-1068 |
|---|
| ISSN Quelle: | 1476-5551 |
|---|
| Abstract: | The optimal timing of allogeneic hematopoietic stem cell transplantation (HCT) in acute myeloid leukemia (AML) is controversial. We report on 1179 patients with a median age of 48 years who were randomized upfront. In the control arm, sibling HCT was scheduled in the first complete remission for intermediate-risk or high-risk AML and matched unrelated HCT in complex karyotype AML. In the experimental arm, matched unrelated HCT in first remission was offered also to patients with an FLT3-ITD (FMS-like tyrosine kinase 3-internal tandem duplication) allelic ratio >0.8, poor day +15 marrow blast clearance and adverse karyotypes. Further, allogeneic HCT was recommended in high-risk AML to be performed in aplasia after induction chemotherapy. In the intent-to-treat (ITT) analysis, superiority of the experimental transplant strategy could not be shown with respect to overall survival (OS) or event-free survival. As-treated analyses suggest a profound effect of allogeneic HCT on OS (HR 0.73; P=0.002) and event-free survival (HR 0.67; P<0.001). In high-risk patients, OS was significantly improved after allogeneic HCT in aplasia (HR 0.64; P=0.046) and after HCT in remission (HR 0.74; P=0.03). Although superiority of one study arm could not be demonstrated in the ITT analysis, secondary analyses suggest that early allogeneic HCT is a promising strategy for patients with high-risk AML. |
|---|
| DOI: | doi:10.1038/leu.2014.335 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1038/leu.2014.335 |
|---|
| | Volltext: https://www.nature.com/articles/leu2014335 |
|---|
| | DOI: https://doi.org/10.1038/leu.2014.335 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1701043351 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Hematopoietic cell transplantation in patients with intermediate and high-risk AML / Schetelig, Johannes [VerfasserIn]; 2015 (Online-Ressource)
